Daniel Shelly tasked to build deals at PolTREG

21 February 2024

PolTREG (Warsaw Stock Exchange: PTG), a Polish biotech developing cell therapies for autoimmune diseases, has named Daniel Shelly its chief business development officer.

Professor Shelly has been tasked with building the strategic, commercial, research and pharmaceutical partnerships that will enable the Polish company to successfully commercialize its pipeline of cell therapies for diseases such as Type-1 diabetes (T1D), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).

"PolTREG has the most comprehensive pipeline of cell therapies for autoimmune diseases"Piotr Trzonkowski, chief executive of PolTREG, said: "I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases. PolTREG has the most comprehensive pipeline of cell therapies for autoimmune diseases, including T1D and MS, and Dan’s arrival will enable us to continue to deliver the milestones that will bring our lead assets closer to market."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK